Theme: Advances in Immunotherapy
Reviews
Klin Onkol 2017; 30(S3): 6-9.
DOI: 10.14735/amko20173S6.
Keywords: bladder cancer – imunotherapy – PD-1 receptor – antibodies – monoclonal
Authors: Büchler Tomáš2017-12-14:Immunotherapy for Bladder Cancer
Keywords: bladder cancer – imunotherapy – PD-1 receptor – antibodies – monoclonal
Authors: Büchler Tomáš2017-12-14:Immunotherapy for Bladder Cancer
Klin Onkol 2017; 30(S3): 10-21.
DOI: 10.14735/amko20173S10.
Keywords: solid tumors – tumor-infiltratig lymphocytes – inflammatory cells
Authors: Dundr Pavel, Němejcová Kristýna, Bártů Michaela, Matěj Radoslav, Rohan Zdeněk, Tichá Ivana2017-12-14:Evaluation of Inflammatory Cells (Tumor Infiltrating Lymphocytes) in Solid Tumors
Keywords: solid tumors – tumor-infiltratig lymphocytes – inflammatory cells
Authors: Dundr Pavel, Němejcová Kristýna, Bártů Michaela, Matěj Radoslav, Rohan Zdeněk, Tichá Ivana2017-12-14:Evaluation of Inflammatory Cells (Tumor Infiltrating Lymphocytes) in Solid Tumors
Klin Onkol 2017; 30(S3): 22-31.
DOI: 10.14735/amko20173S22.
Keywords: immunotherapy – lung cancer – NSCLC – SCLC – checkpoint inhibitors
Authors: Fiala Ondřej, Šorejs Ondřej, Pešek Miloš, Fínek Jindřich2017-12-14:Immunotherapy in the Treatment of Lung Cancer
Keywords: immunotherapy – lung cancer – NSCLC – SCLC – checkpoint inhibitors
Authors: Fiala Ondřej, Šorejs Ondřej, Pešek Miloš, Fínek Jindřich2017-12-14:Immunotherapy in the Treatment of Lung Cancer
Klin Onkol 2017; 30(S3): 32-39.
DOI: 10.14735/amko20173S32.
Keywords: RECIST – response criteria – immunotherapy – measurement – tumor burden
Authors: Houdek Štěpán, Büchler Tomáš, Kindlová Eva2017-12-14:Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours
Keywords: RECIST – response criteria – immunotherapy – measurement – tumor burden
Authors: Houdek Štěpán, Büchler Tomáš, Kindlová Eva2017-12-14:Comparison of RECIST 1.1 and iRECIST for Response Evaluation in Solid Tumours
Klin Onkol 2017; 30(S3): 40-44.
DOI: 10.14735/amko20173S40.
Keywords: malignant melanoma – immunotherapy – ipilimumab – nivolumab – pembrolizumab – talimogene laherparepvec – brain metastases
Authors: Krajsová Ivana2017-12-14:Advances in Immunotherapy of Malignant Melanoma
Keywords: malignant melanoma – immunotherapy – ipilimumab – nivolumab – pembrolizumab – talimogene laherparepvec – brain metastases
Authors: Krajsová Ivana2017-12-14:Advances in Immunotherapy of Malignant Melanoma
Klin Onkol 2017; 30(S3): 45-49.
DOI: 10.14735/amko20173S45.
Keywords: immunotherapy – ipilimumab – nivolumab – pembrolizumab
Authors: Melichar Bohuslav, Spisarová Martina2017-12-14:Combined Regimens in Immunotherapy
Keywords: immunotherapy – ipilimumab – nivolumab – pembrolizumab
Authors: Melichar Bohuslav, Spisarová Martina2017-12-14:Combined Regimens in Immunotherapy
Klin Onkol 2017; 30(S3): 50-54.
DOI: 10.14735/amko20173S50.
Keywords: esophageal cancer – stomach cancer – checkpoint inhibitors
Authors: Obermannová Radka2017-12-14:Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors
Keywords: esophageal cancer – stomach cancer – checkpoint inhibitors
Authors: Obermannová Radka2017-12-14:Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors
Klin Onkol 2017; 30(S3): 55-61.
DOI: 10.14735/amko20173S55.
Keywords: renal cell carcinoma – immunotherapy – checkpoint inhibitors – target therapy
Authors: Poprach Alexandr, Lakomý Radek, Büchler Tomáš2017-12-14:Immunotherapy of Renal Cell Carcinoma
Keywords: renal cell carcinoma – immunotherapy – checkpoint inhibitors – target therapy
Authors: Poprach Alexandr, Lakomý Radek, Büchler Tomáš2017-12-14:Immunotherapy of Renal Cell Carcinoma
Klin Onkol 2017; 30(S3): 62-65.
DOI: 10.14735/amko20173S62.
Keywords: cancer immunotherapy – checkpoint inhibitors – colorectal cancer – anal cancer – nivolumab – pembrolizumab
Authors: Tomášek Jiří, Kiss Igor2017-12-14:Immunotherapy of Colorectal and Anal Carcinoma
Keywords: cancer immunotherapy – checkpoint inhibitors – colorectal cancer – anal cancer – nivolumab – pembrolizumab
Authors: Tomášek Jiří, Kiss Igor2017-12-14:Immunotherapy of Colorectal and Anal Carcinoma
